Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Understanding the Modern “Fatty Liver” Disease

MASLD is a common liver condition associated with metabolic health. Understanding its risk factors, progression, diagnosis, and prevention can help reduce the risk of advanced liver disease.

Understanding MASLD Metabolic dysfunction-associated steatotic liver disease MASLD is a condition in which excess fat accumulates in the liver in association with one or more cardiometabolic risk factors. It was previously known as non-alcoholic fatty liver disease NAFLD. The terminology was updated in 2023 to better reflect the metabolic factors associated with the disease. MASLD exists across a spectrum. Some people have simple liver steatosis, while others can develop inflammation, liver-cell injury, fibrosis, cirrhosis, and complications such as liver cancer. The inflammatory form is called metabolic dysfunction-associated steatohepatitis MASH. Why Does MASLD Develop? MASLD is closely associated with metabolic risk factors such as excess body weight, prediabetes or type 2 diabetes, high blood pressure, abnormal cholesterol levels, and other features of metabolic dysfunction. These factors can contribute to the accumulation of fat within liver cells and, in some individuals, progressive liver injury. The condition is also closely connected with overall cardiovascular and metabolic health. This makes MASLD more than simply a liver problem—it is part of a broader metabolic health picture. From Fat Accumulation to Liver Damage Not everyone with liver fat develops serious liver disease. However, persistent inflammation and cellular injury can promote the development of fibrosis, in which scar tissue gradually accumulates in the liver. Advanced fibrosis can progress to cirrhosis and can increase the risk of serious complications. MASLD-related liver disease can also be associated with hepatocellular carcinoma, a major form of primary liver cancer. How Is MASLD Identified? Evaluation generally considers a person's metabolic risk factors together with evidence of hepatic steatosis. Imaging and laboratory tests may help identify liver fat and assess liver health. When appropriate, clinicians can use non-invasive fibrosis assessment tools to estimate the likelihood of advanced fibrosis. AASLD notes that FIB-4 can be used as an initial fibrosis assessment in appropriate adults, with additional testing considered when indicated. Diagnosis should also consider other possible causes of liver disease rather than assuming that every case of liver fat represents MASLD. Prevention and Management !Article image/api/blog/covers/1787984978075-c87bf8357f99b0ef845aeeb2444b47dc.webp Lifestyle and metabolic health are central to MASLD management. Improving diet quality, increasing regular physical activity, managing body weight, and addressing conditions such as diabetes, hypertension, and abnormal blood lipids can be important components of care. Management should be individualized according to disease severity and the presence of fibrosis or other medical conditions. People with suspected or diagnosed MASLD should discuss appropriate evaluation and treatment with a qualified healthcare professional. Why MASLD Matters MASLD is increasingly recognized as an important global health challenge. Its close relationship with obesity, type 2 diabetes, cardiovascular risk, and other metabolic conditions makes early recognition particularly important. Understanding MASLD also helps move the conversation beyond the older term “fatty liver.” The newer terminology highlights the role of metabolic dysfunction and provides a more precise framework for describing the different forms and stages of steatotic liver disease.

Author: NIMAN BAIRWA